The importance of MRD assessment in all phases of ALL treatment
iwNHL 2015 roundtable: Day 2 highlights – CAR T-cell therapy for non-Hodgkin lymphoma
John Gribben et al.
Why the rapid development of new drugs poses new challenges
From Structure to Function to Clinical Outcome
How to generate an anticancer immune response in multiple myeloma